Medical &lt;i&gt;Cannabis&lt;/i&gt;: A guide to the clinical and legal landscapes

,; ,

Applied Evidence

Medical Cannabis: A guide to the clinical and legal landscapes

J Fam Pract. 2019 September;68(7):390-394,396-399

PDF Download

References

1. College of Family Physicians of Canada. Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada. Mississauga, Ontario: College of Family Physicians of Canada; 2014. www.cfpc.ca/uploadedFiles/Resources/_PDFs/Authorizing%20Dried%20Cannabis%20for%20Chronic%20Pain%20or%20Anxiety.pdf. Accessed July 10, 2019.

2. Hartig H, Geiger AW. About six-in-ten Americans support marijuana legalization. Pew Research Center Web site. www.pewresearch.org/fact-tank/2018/10/08/americans-support-marijuana-legalization/. Published October 8, 2018. Accessed July 10, 2019.

3. Li H-L. An archaeological and historical account of cannabis in China. Econ Bot. 1974:28:437-448.

4. Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28:153-157.

5. Marijuana strains and infused products. Leafly Web site. www.leafly.com/start-exploring. Accessed July 10, 2019.

6. Fraguas-Sánchez AI, Torres-Suárez AI. Medical use of cannabinoids. Drugs. 2018;78:1665-1703.

7. Maurya N, Velmurugan BK. Therapeutic applications of cannabinoids. Chem Biol Interact. 2018;293:77-88.

8. Kelkar AH, Smith NA, Martial A, et al. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med. 2018;379:1216-1223.

9. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ⁹-tetrahydrocannabinol, cannabidiol and Δ⁹-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199-215.

10. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473.

11. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2008;34:672-680.

12. US Department of Justice, Drug Enforcement Administration, Diversion Control Division. Title 21 United States Code (USC) Controlled Substances Act. Subchapter I—Control and Enforcement. Part A—Introductory Provisions. §801. Congressional findings and declarations: controlled substances. www.deadiversion.usdoj.gov/21cfr/21usc/801.htm. Accessed July 10, 2019.

13. Yeh BT. The Controlled Substances Act: regulatory requirements. Congressional Research Service 7-5700. https://fas.org/sgp/crs/misc/RL34635.pdf. Published December 13, 2012. Accessed July 10, 2019.

14. US Department of Justice, Drug Enforcement Administration, Diversion Control Division. Title 21 United States Code (USC) Controlled Substances Act. Subchapter I—Control and Enforcement. Part B—Authority to Control; Standards and Schedules. §812. Schedules of controlled substances. www.deadiversion.usdoj.gov/21cfr/21usc/812.htm. Accessed July 10, 2019.

15. United States Senate. The STATES Act. Senator Elizabeth Warren and Senator Cory Gardner. 2018. www.warren.senate.gov/imo/media/doc/STATES%20Act%20One%20Pager.pdf. Accessed July 10, 2019.

16. Strengthening the Tenth Amendment Through Entrusting States (STATES) Act of 2019, HR 2093. 116th Cong, 1st Session (2019). www.congress.gov/bill/116th-congress/house-bill/2093/text. Accessed July 20, 2019.

17. Strengthening the Tenth Amendment Through Entrusting States (STATES) Act of 2019, S 1028. 116th Cong, 1st Session (2019). www.congress.gov/bill/116th-congress/senate-bill/1028/all-info?r=3&s=6. Accessed August 8, 2019.

18. State medical marijuana laws. National Conference of State Legislatures Web site. www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3. Published July 2, 2019. Accessed July 10, 2019.

19. Conant v Walters. 309 F.3d 629 (9th cir. 2002).

20. American Society of Addiction Medicine. The role of the physician in “medical” marijuana. www.asam.org/docs/publicy-policy-statements/1role_of_phys_in_med_mj_9-10.pdf?sfvrsn=0. Published September 2010. Accessed July 12, 2019.

21. What are marijuana’s effects on lung health? National Institute on Drug Abuse Web site. www.drugabuse.gov/publications/research-reports/marijuana/what-are-marijuanas-effects-lung-health. Updated July 2019. Accessed July 10, 2019.

22. Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10:239-247.

23. Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer. 2015;136:894-903.

24. Getting medical marijuana. Commonwealth of Pennsylvania Web site. www.pa.gov/guides/pennsylvania-medical-marijuana-program/. Accessed July 20, 2019.

25. Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181-192.

26. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24:515-523.

27. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.

28. Barrus DG, Capogrossi KL, Cates S, et al. Tasty THC: Promises and Challenges of Cannabis Edibles. Publication No. OP-0035-1611. Research Triangle Park, NC: RTI Press; 2016. www.rti.org/sites/default/files/resources/rti-publication-file-6ff047d7-3fa4-41ad-90ed-9fb11663bc89.pdf. Accessed July 10, 2019.

29. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12-19.

30. MacCoun RJ, Mello MM. Half-baked—the retail promotion of marijuana edibles. N Engl J Med. 2015;372:989-991.

31. Cannabis use disorder [305.20, 304.30]. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Washington, DC: American Psychiatric Association; 2013:509-516.

32. Williams AR, Santaella-Tenorio J, Mauro CM, et al. Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction. 2017;112:1985-1991.

33. American Academy of Pediatrics Committee on Substance Abuse, American Academy of Pediatrics Committee on Adolescents. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135:584-587.

34. Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017;140. pii: e20171818.

35. Drug Enforcement Administration. Drugs of abuse: a DEA resource guide. www.dea.gov/sites/default/files/drug_of_abuse.pdf. Published 2017. Accessed July 10, 2019.

36. National Academies of Science, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. www.nap.edu/read/24625/chapter/12017:2017-2019. Published 2017. Accessed July 10, 2019.

37. Emerging trend and alerts. National Institute on Drug Abuse Web site. www.drugabuse.gov/drugs-abuse/emerging-trends-alerts. Accessed July 10, 2019.

38. Drug Policy Alliance. From prohibition to progress: a status report on marijuana legalization. www.drugpolicy.org/sites/default/files/dpa_marijuana_legalization_report_feb14_2018_0.pdf. Published January 2018. Accessed July 10, 2019.

Overconsumption of edibles. Cannabis edibles (ie, food products infused with Cannabis extract) are distinct from inhaled Cannabis in regard to onset, duration, and potential for adverse effects. Cannabis edibles might be more popular than inhaled products among older medical Cannabis users.²⁸

Edible Cannabis has a reported onset of 1 to 3 hours (compared to 5-10 minutes with inhaled Cannabis) and a duration of effect of 6 to 8 hours (compared with 2-4 hours for inhaled products).²⁹ These qualities might render Cannabis edibles preferable to inhaled formulations for controlling chronic symptoms and conditions. However, delayed onset of edible products and wide variation in the concentration of THC also increase the risk of overconsumption, which can lead to overdose and self-limited Cannabis-induced psychosis. We recommend providing patient education about the effects of the physiologically active therapeutic compounds tetrahydrocannabinol and cannabidiol, to prevent overconsumption of high-THC products.³⁰

CASE

Mr. S returns to your office after a trial of Cannabis as vaporized oil and reports some relief of nausea and a mild increase in appetite, but no weight gain. He is concerned about overconsumption or overdose, and asks you what the risks of these problems are.

How should you counsel Mr. S? Explain that ingestion of Cannabis has a prolonged onset of action; vaporization has a more rapid onset of action; therefore, he could more easily self-regulate ingestion with the vehicle he has chosen. In states where edible Cannabis products are legal, education is necessary so that patients know how much of the edible to consume and how long they will wait to feel the full impact of the effects of THC.³⁰

Cannabis use disorder in the context of medical marijuana

Cannabis use disorder (CUD) incorporates general diagnostic features of a substance use disorder, including behavioral, cognitive, and physiologic symptoms such as cravings, tolerance, and withdrawal, in the setting of persistent use despite significant substance-related problems.³¹ Features of Cannabis withdrawal syndrome include irritability, anger or aggression, anxiety, depressed mood, restlessness, sleep difficulty, and decreased appetite or weight loss.³¹ Cannabis use disorder can develop in people who use medical Cannabis; however, physiologic symptoms of tolerance and withdrawal can also develop in the setting of appropriate medical use and do not, in isolation, represent CUD.

Continue to: A recent study...